MIDAGLIZOLE DIHYDROCHLORIDE

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H17N3.2ClH
Molecular Weight	324.248
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of MIDAGLIZOLE DIHYDROCHLORIDE

SMILES

Cl.Cl.C(C(C1=CC=CC=C1)C2=NC=CC=C2)C3=NCCN3

InChI

InChIKey=PAKRIOPMNVCTCL-UHFFFAOYSA-N

InChI=1S/C16H17N3.2ClH/c1-2-6-13(7-3-1)14(12-16-18-10-11-19-16)15-8-4-5-9-17-15;;/h1-9,14H,10-12H2,(H,18,19);2*1H

HIDE SMILES / InChI

Molecular Formula	C16H17N3
Molecular Weight	251.3263
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count	MOL RATIO 2 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Midaglizole (also known as DG 5128) is a α2 adrenoceptor antagonist. Daiichi Pharmaceutical developed this drug as an oral antidiabetic agent and to treat asthma. However, further study of this drug was discontinued.

Originator

Approval Year

PubMed

PubMed

Show entries

Title	Date	PubMed
Metabolic fate of the oral hypoglycaemic agent, midaglizole, in rats.	1989 Jun	2669362
Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part I: Respiratory and cardiovascular systems.	1991 Jan	1675573
Effect of an alpha 2-adrenoceptor antagonist, midaglizole, on bronchial responsiveness to histamine in patients with mild asthma.	1995	7629001

Showing 1 to 3 of 3 entries

Previous1Next

Sample Use Guides

In Vivo Use Guide

Oral administration of DG-5128 (MIDAGLIZOLE) significantly (P less than .05) enhanced insulin secretion both 30 and 60 min after a mixed meal (550 kcal), with a concomitant decrease in postprandial plasma glucose levels at 60 and 120 min

Route of Administration: Oral